07.07.25
How tightly should you stick to a GA therapy’s label? Which complement inhibitor do you pick and why? And which candidates are best suited for treatment? In part 1 of this 2-part series, moderator Judy Kim, MD, and panelists Sunir Garg, MD; Deepak Sambhara, MD, and Rishi Singh, MD, explore these questions in a brief (but enlightening) discussion.
View full description +
Editorially independent content, supported by Apellis
Subscribe
10.10.25
New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient CareNiki Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD
Editorially Independent Content Supported by Genentech
10.09.25
The Nuts and Bolts of GA Therapy: The Opening SessionsCharles Wykoff, MD, PhD; with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
10.02.25
Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring VisionJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
10.02.25
Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and PhotobiomodulationJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
10.02.25
Keeping Patients at the Center of GA Therapy: Patient Education and Setting ExpectationsJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
10.02.25
Keeping Patients at the Center of GA Therapy: Social Impact and Early InterventionJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
09.26.25
New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From FaricimabEditorially Independent Content Supported by Genentech and Astellas.
09.04.25
ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDRDavid Lally, MD; and Ehsan Rahimy, MD
Editorially independent content, supported by Genentech
Show More